UnknownNot Applicable

Prolactin and FGF21 in Gestational Diabetes Mellitus

China200 participantsStarted 2017-01-01

Plain-language summary

Prolactin (PRL) and PRL receptor (PRLR) signaling has been validated to play an important role in the modulation of glucolipid metabolism. However, the role of serum PRL levels in gestational diabetes mellitus (GDM) remains unclear. The investigators aimed to explore the possible influence of serum PRL within or without normal range on the development of GDM.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * aged 18 to 45 years * completed a 75-g oral glucose tolerance test (OGTT) * females with pregnancy Exclusion Criteria: * severe liver and renal dysfunction, preexisting heart disease, malignancy, or endocrine diseases such as pituitary adenoma and hypogonadism * mental illness * genetic disease * current or previous treatment that might affect PRL and insulin secretion * diabetes before pregnancy * loss to follow-up, or withdrawal from the study * unable to understand and comply with the study protocol.

What they're measuring

Gestational diabetes mellitus (GDM)

Timeframe: 2019-2023

PRL

Timeframe: 2019-2023

Trial details

NCT IDNCT05528393

SponsorShen Qu

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-09-01

View on ClinicalTrials.gov More Gestational Diabetes Mellitus in Pregnancy trials